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Protein phosphorylation and protein ubiquitination regulate most aspects of cell life, and defects in
these control mechanisms cause cancer and many other diseases. In the past decade, protein
kinases have become one of the most important classes of drug targets for the pharmaceutical
industry. In contrast, drug discovery programs that target components of the ubiquitin system
have lagged behind. In this Perspective, we discuss the reasons for the delay in this pipeline, the
drugs targeting the ubiquitin system that have been developed, and new approaches that may
popularize this area of drug discovery in the future.Protein Phosphorylation Drug Discovery
It can take years, even decades, before a field of research rea-
ches the stage of maturity at which its discoveries can obviously
be exploited for the improvement of health. An excellent example
of this paradigm is the regulation of protein function by reversible
phosphorylation. Phosphorylation was identified in the mid
1950s as a mechanism for controlling glycogenolysis. Twenty-
five years later, it was still largely thought of simply as a control
switch for metabolism. Indeed, researchers finally realized that
protein phosphorylation regulates most aspects of cell life only
after many advances made throughout the 1980s and early
1990s (Cohen, 2002a).
Surprisingly, the idea that it would be possible to treat diseases
with drugs targeting protein kinases was even slower to take
root. Indeed, as late as 1998, theHead of Research andDevelop-
ment at one major pharmaceutical company (which no longer
exists) told one of the authors that ‘‘there was absolutely no
future in kinase drug discovery.’’ Later that same year,
researchers revealed the remarkable clinical efficacyof a tyrosine
kinase inhibitor, called Gleevec, for treating chronic myeloge-
nous leukemia. Quite quickly, protein kinases then became one
of the most popular classes of drug targets for the pharmaceu-
tical industry, especially in the field of cancer treatment.
Over the past decade, 16 drugs targeting one or more protein
kinases have been approved for clinical use in cancer, 12 taken
orally as pills and 4 that are injected. As of 2009, 153 other
protein kinase inhibitors were undergoing clinical trials, and 23
of these drugs were in themost advanced stage of development,
termed Phase III (Table 1) (Lawler, 2009). The current global
market for kinase therapies is about US$15 billion per annum,
and this value is forecasted to double by 2020. Research on
protein kinases currently accounts for 30% of the drug
discovery programs in the pharmaceutical industry and over
50% of cancer research and development. The kinase inhibitors686 Cell 143, November 24, 2010 ª2010 Elsevier Inc.undergoing Phase III clinical trials include Pfizer’s JAK3 inhibitor
for rheumatoid arthritis (CP-690550) and Incyte Pharmaceuti-
cal’s JAK1/JAK2 inhibitor (INCB18424) for treating inflammatory
diseases. If these drugs are approved, it will likely spark a new
wave of interest in developing kinase inhibitors for the treatment
of diseases other than cancer.
Even by the late 1970s and early 1980s researchers had shown
that oncogenes, such as Src (sarcoma), are protein kinases;
phorbol esters, which promote tumors, are kinase activators;
and, growth factor receptors, which have kinase domains, are
overexpressed or mutated in human cancer (reviewed in Cohen,
2002b). So why did it take so long for most pharmaceutical
companies to capitalize on the therapeutic potential of kinase
inhibitors? In retrospect, one realizes that many researchers
believed that kinase inhibitors were bad drug targets because
they thought that it would be difficult to achieve the requisite
specificity and potency. Most protein kinase inhibitors target
the ATP-binding pockets of these enzymes, and the structural
similarities of this site among many different kinases raised the
suspicion that it would be impossible to develop drugs that in-
hibited only one type of protein kinase. Furthermore, the concen-
tration of ATP in the cell is extremely high (i.e., millimolar), leading
researchers to doubt whether compounds could be developed
with the potency needed to compete successfully with intracel-
lular ATP. These were, and indeed still are, challenging problems
formany developing kinase inhibitors, but they have proven to be
quite surmountable.
Indeed, considerable potency and specificity have been
achieved by developing compounds that target not only the
ATP-binding site but also small hydrophobic pockets located
proximal to the ATP-binding site. Moreover, researchers are
identifying an increasing number of ‘‘allosteric’’ inhibitors that
bind to other regions of a kinase. These compounds induce
conformational changes in the kinase, which either suppress
Table 1. Phosphorylation, Ubiquitination, and Drug Discovery
Phosphorylation Ubiquitination
First publication 1955a First publication 1978b
>500 protein kinasesc 10 E1sf, 40 E2sf, >600 E3 ligasesf
140 protein phosphatasesc 90 deubiquitinasesc
Nobel Prize awarded 1992d Nobel Prize awarded 2004e
First drug approved in 2001 (Gleevec) First drug approved in 2003 (Bortezomib)
16 drugs approved, over 150 undergoing clinical trials One drug approved, 16 undergoing clinical trials
Current sales US$15 billion per year Current sales US$1.4 billion per year
30% of pharmaceutical research and development <1% of pharmaceutical research and development
a Fischer and Krebs, 1955.
bCiechanover et al., 1978.
c Encoded by the human genome.
dNobel Prize for Physiology or Medicine awarded to Edmond Fischer and Edwin Krebs.
eNobel Prize for Chemistry awarded to Aaron Ciechanover, Avram Hershko, and Irwin Rose.
f Includes the E1s and E2s for ubiquitin-related modifiers such as Nedd8, SUMO, FAT10, and ISG15.the enzyme’s activity directly or block its activation by another
kinase in the same signaling cascade.
Furthermore, far from being a disadvantage, lack of specificity
can actually be an advantage. For example, Gleevec was devel-
oped as an Abelson kinase inhibitor for the treatment of a specific
type of leukemia. However, it is also an effective treatment for
gastrointestinal stromal cancers because it inhibits the c-Kit
receptor and the platelet-derived growth factor (PDGF) receptor
tyrosine kinases, which are overexpressed or mutated in gastro-
intestinal cancers (Demetri et al., 2006). In addition, the efficacy
of several anticancer drugs depends on their combined inhibition
of several different kinases, and these drugs may be less prone
to the development of drug resistance than ones that act on only
one specific kinase. Thus, some of the original prejudices against
protein kinases as drug targets have subsequently turned out to
have little substance.
The beauty of targeting protein kinases for therapeutics and
the basis for their popularity is that the same technologies and
small-molecule libraries can be used to develop inhibitors of
many types of protein kinases in almost every therapeutic
area. However, the vast amount of medicinal chemistry that
has been carried out in recent years has meant that novel patent
space is becoming quite difficult to find. Plus, there is a growing,
but probably unfounded, concern that the most important drug
targets in this area have been fully exploited. Therefore, the phar-
maceutical industry has begun to wonder where they may find
the next large set of drug targets that can be tackled in a manner
analogous to protein kinases. In this Perspective, we discuss the
premise that components of the ubiquitin system are prime
candidates for these new targets.Ubiquitination More Versatile than Phosphorylation?
Ubiquitination is the covalent attachment of a small protein,
ubiquitin (8.5 kDa), to other proteins. In the first step, a thioester
bond is formed between the C-terminal carboxylate group of
ubiquitin and the thiol or sulfhydryl group of a cysteine residue
on an E1-activating enzyme. Next, the ubiquitin is transferred
to a cysteine on an E2-conjugating enzyme. In the third step,the E2 interacts with an E3 ligase, and the ubiquitin is then trans-
ferred from the E2 enzyme to substrates, which also interact with
the E3 ligase. This last step can occur directly, as in the RING E3
ligases, or it can occur indirectly with the ubiquitin first trans-
ferred to a cysteine residue on the E3 ligase before being linked
to the substrate, as in the HECT family of E3 ligases. Chains of
ubiquitin are created by the same enzymatic process.
Similar to phosphorylation, ubiquitin can be linked covalently
to only one or several amino acid residues on the same protein
(Figure 1). However, in contrast to protein phosphorylation, ubiq-
uitin can also form polyubiquitin chains. Ubiquitin has seven
lysine residues and an a-amino group; thus eight different types
of polyubiquitin chains can form (and probably more because
chains with ‘‘mixed’’ linkages are also present in cells).
Even greater versatility is provided by ubiquitin-like proteins,
such as Nedd8, SUMO (1, 2, and 3), FAT10, and ISG15, which
are also attached covalently to proteins in processes called ned-
dylation, SUMOylation, tenylation, and ISGylation, respectively.
The formation of polyubiquitin chains and the existence of these
‘‘ubiquitin-like modifiers’’ make the ubiquitin system a more
complex and potentially more versatile control mechanism
than phosphorylation.
Like phosphorylation, ubiquitination is reversible. Isopepti-
dases, called deubiquitinases or DUBs, catalyze the cleavage
of the ubiquitin from proteins or ‘‘deubiquitination’’ (Figure 1).
Interestingly, the number of deubiquitinases is comparable to
the number of protein phosphatases, but taken together, the
number of E1-activating enzymes, E2-conjugating enzymes,
and E3 ligases encoded by the human genome exceeds the
number of protein kinases.Ubiquitination and Phosphorylation: Analogous Control
Mechanisms
For many years, the sole function of the ubiquitin system was
thought to be the regulation of protein turnover inside the cell. At-
taching a chain of ubiquitins linked at lysine 48 (K48-linked poly-
ubiquitination) to a protein directs it to the 26S proteasome for
destruction, and indeed, this is one of the key functions of theCell 143, November 24, 2010 ª2010 Elsevier Inc. 687
Figure 1. Phosphorylation and Ubiquitina-
tion Regulate Most Aspects of Cell Life
Phosphorylation involves the covalent attachment
of phosphate to proteins, mainly to serine, threo-
nine, and tyrosine residues. Phosphorylation is
catalyzed by protein kinases and reversed by
protein phosphatases. Protein ubiquitination
involves the covalent attachment of ubiquitin,
a small protein with 76 amino acids, to other
proteins, predominantly to lysine residues. This
reaction is mediated by an E1-activating enzyme,
an E2-conjugating enzyme, and an E3 ligase; this
reaction is reversed by deubiquitinases.ubiquitin system. However, other types of ubiquitination play
distinct roles in the cell and regulate diverse areas of biology,
as discussed in another article in this issue (Ikeda et al., 2010).
For example, K63-linked polyubiquitination (Bhoj and Chen,
2009; Zeng et al., 2010) and linear polyubiquitin chains
(Tokunaga et al., 2009) regulate innate immunity; K11-linked pol-
yubiquitin chains, which are formed by the anaphase-promoting
complex (APC/C) and the E2-conjugating enzyme UbcH10,
are critical for the regulation of mitosis (Garnett et al., 2009;
Jin et al., 2008); and K29/33-linked polyubiquitination inhibits
certain members of a protein kinase subfamily (Al-Hakim et al.,
2008).
Like phosphorylation, ubiquitination can also induce confor-
mational changes that alter biological function. For example,
the response to the proinflammatory cytokine interleukin-1 (IL-
1) generates K63-linked polyubiquitin chains that interact with
a component of the TAK1 complex, inducing a conformational
change that allows this protein kinase to autoactivate (Xia
et al., 2009). Similarly, monoubiquitination of the deubiquitinase
Ataxin 3 (Todi et al., 2009) and dihydrofolate reductase (Maguire
et al., 2008) enhances and suppresses their enzymatic activities,
respectively. In contrast, monoubiquitination of the tumor
suppressor p53 induces a conformational change that exposes
a nuclear export signal. This leads to the translocation of p53
to the cytosol where it may promote apoptotic events (Carter
et al., 2007). Neddylation of the Cullin RING E3 ligases (CRLs)
also induces conformational changes that bring the E2 active
site adjacent to the substrate, permitting the efficient ubiquitina-
tion of the substrate by CRLs (Saha and Deshaies, 2008).
Like phosphorylation, many effects of ubiquitination are medi-
ated by interactions with ubiquitin-binding proteins. Different
polyubiquitin chains adopt distinct three-dimensional structures
and hence interact with different polyubiquitin-binding proteins
to regulate distinct processes. For example, proteins tagged
with K48-linked polyubiquitin chains are targeted for destruction
because these ubiquitin chains bind to particular components of
the 26S proteasome. More than 20 different families of polyubi-
quitin-binding proteins have been identified, and this area has
become a large topic of research in its own right.
Interactions through ubiquitin are also critical for DNA-damage
signaling and for certain DNA-repair pathways. For example, the
monoubiquitinated formof FANCD2, a component of the Fanconi
Anemia Complex, interacts with the UBZ domain of the DNA
nuclease FAN1, and this interaction through ubiquitin is essential
for repair of DNA interstrand crosslinks (MacKay et al., 2010).688 Cell 143, November 24, 2010 ª2010 Elsevier Inc.K63-linked polyubiquitin chains attached to histone 2A and
histone 2AX by the E3 ligase RNF8 and the E2 -conjugating
enzyme Ubc13 (Kolas et al., 2007) recruit and assemble factors
that are essential for DNA repair, such as BRCA1 (breast cancer
1), RAP80, and other proteins (Bennett and Harper, 2008).
It is important to emphasize that protein phosphorylation and
protein ubiquitination are not distinct and separate control mech-
anisms because the interplay between them is critical for the
regulation of many cellular processes. For example, phosphoryla-
tion regulates a number of E3 ubiquitin ligases and deubiquiti-
nases. Further, the E3 ligase Skp1-Cullin-F box (SCF) and some
other E3 ligases contain an additional component bTRCP
(b-transducin repeat-containing protein), which recognizes partic-
ular phosphorylated sequence motifs that direct the SCFbTRCP
complex to ubiquitinate these substrates. Finally, a number of
kinases can be activated or inhibited by interactions with polyubi-
quitin chains or by polyubiquitination. Given the omnipresence of
protein phosphorylation and ubiquitination inside the cell, under-
standing the interplay between these two systems is likely to
become increasingly more important over the next decade.
Developing Drugs that Target the Ubiquitin System
The Proteasome Inhibitor Bortezomib
The protease inhibitor Bortezomib, originally called PS341 and
then Velcade (Adams, 2002), was the first drug that targets
a component of the ubiquitin system to be approved for clinical
use in the United States. Developed by ProScript Inc in 1995,
Bortezomib entered clinical trials in 1997 and was approved by
the Federal Drug Administration in 2003. In 1999 ProScript was
acquired by Leukosite, which in turn was acquired by Millenium
Pharmaceuticals later that same year. Bortezomib has been
quite successful, with worldwide sales in 2009 of US$1.4 billion,
and this achievement led Takeda to acquire Millenium in 2008.
Bortezomib was approved as a front-line treatment for B cell
lymphoma found primarily in the bone marrow. It is also used
for the treatment of mantle cell lymphoma in patients who have
already received other treatments. It is in Phase III clinical trials
for follicular non-Hodgkin’s lymphoma, Phase II trials for diffuse
large B cell lymphoma, and a great many other clinical trials (re-
viewed in Tcherpakov, 2010).
Bortezomib, which is given by intravenous injection, has
remarkable efficacy against multiple myeloma, but themolecular
mechanism underlying its effect is still unclear. Nevertheless, the
multiple myeloma cells that are particularly sensitive to protea-
some inhibitors express lower levels of proteasome particles
Table 2. Proteasome Inhibitors Approved or in Clinical Trials
Company Inhibitor Development Stage Disease
Millenium/Takeda Bortezomib/Velcade Approved Multiple myeloma and mantle cell lymphoma
Millenium/Takeda MLN9708 Phase I Multiple myeloma and other cancers
ONYX (Proteolix) Carfilzomib/PR171 Phase III Multiple myeloma and other cancers
ONYX (Proteolix) Onx 0912/PR047 Phase I Multiple myeloma and other cancers
Cephalon CEP18770 Phase I Multiple myeloma and other cancers
Nereus Pharmaceuticals Salinosporamid A/NPI0052 Phase I Multiple myeloma and leukemiaand have a higher proteasome workload than multiple myeloma
cells that are relatively resistant to these drugs. Thus, the balance
betweenproteasomeworkloadanddegradative capacitymaybe
an important determinant of the sensitivity of a cancer cell to
Bortezomib and other proteasome inhibitors (Bianchi et al.,
2009).
A dipeptidyl boronic acid, Bortezomib binds noncovalently to
the 20S proteasome and primarily inhibits its chymotrypsin-like
activity (Kisselev et al., 2006). Its success has led to considerable
interest in developing improved ‘‘second generation’’ inhibitors,
and Millenium/Takeda has another proteasome inhibitor,
MLN9708, which can be taken orally, in Phase 1 clinical trials.
Onyx Pharmaceuticals also has several orally active proteasome
inhibitors in clinical trials, which they obtained through the acqui-
sition of Proteolix. These inhibitors include Carfilzomib, which
has recently entered Phase III trials according to the website
http://clinicaltrials.gov. Other proteasome inhibitors that are
currently undergoing clinical development are listed in Table 2.
An Inhibitor of the E1 Enzyme for Neddylation
The Nedd8 protein shares 60% sequence identity with ubiqui-
tin, and it is conjugated to its target proteins in a similar manner
to ubiquitin, with a specific E1-activating enzyme (NAE-E1) and
the E2-conjugating enzymes Ube2M and/or Ube2F. The primary
target for neddylation appears to be the Cullin components of
Cullin RING E3 ubiquitin ligases. The Cullin RING ligases are
the largest family of E3 ligases in the human genome with more
than 100members (Rabut and Peter, 2008). Neddylation permits
efficient ubiquitination by Cullin RING ligases; neddylation
induces a conformational change in the Cullin component toTable 3. Inhibitors of E1-Activating Enzymes and E3 Ubiquitin Liga
Company Inhibitor Target
Millenium/Takeda MLN4924 NAE-E1b
Roche Nutlin/R7112 E3-Hdm2
Johnson & Johnson JNJ26854165 E3-Hdm2
Genentech/Roche GDC-0152 E3-IAP
Novartis LCL161 E3-IAP
Ascenta Therapeutics AT-406 E3-IAP
Aegera Therapeutics AEG 35156a E3-IAP
Aegera Therapeutics AEG 40826 E3-IAP
Tetralogics Pharma TL 32711 E3-IAP
Astellas Pharma YM155 E3-IAP
aAntisense oligonucleotide.
b The E1-activating enzyme for neddylation.bring the E2 active site adjacent to the lysine residue of its protein
target substrates (Duda et al., 2008; Saha and Deshaies, 2008).
Millenium/Takeda has developed a relatively specific inhibitor
of the NAE-E1 enzyme (Table 3). This compound, MLN4924,
showed promise in mouse models of cancer and has entered
Phase I clinical trials for the treatment of multiple myeloma and
non-Hodgkin’s lymphoma. MLN4924 seems to exert its effect
on these cancers by deregulating DNA synthesis during the S
phase of the cell division cycle. MLN4924 appears to stabilize
Cdt1, a DNA replication licensing factor normally ubiquitinated
by a Cullin RING E3 ligase and then degraded by the proteasome
(Soucy et al., 2009).
Inhibitors of Deubiquitinases
Deubiquitinases comprise five separate gene families. Four
families are cysteine proteinases (the USP, OTU, UCH, and
MJD deubiquitinases), and the other one consists of metallo-
proteinases (the JAMM/MPN domain family). The E3 ligase
HDM2 targets the tumor suppressor p53 for degradation. One
of the cysteine protease deubiquitinases, USP7 (ubiquitin-spe-
cific protease 7), deubiquitinates HDM2, leading to increased
levels of HDM2 and decreased levels of p53. Therefore, two
companies, Progenra and Hybrigenics, have developed inhibi-
tors of USP7 (i.e., P5091 and HBX 41108, respectively) (Colland
et al., 2009), with the hope of promoting the proteasomal degra-
dation of HDM2 by enhancing its polyubiquitination. Reduced
expression of HDM2 would then be expected to increase the
level of p53.
Progenra is also developing inhibitors targeting USP20, and
they are showing interest in agents for USP2a, USP33, andses Undergoing Clinical Trials
Stage Disease
Phase II Multiple myeloma and Hodgkin’s lymphoma
Phase I Blood cancers
and solid tumors
Phase I Multiple myeloma and solid tumors
Phase I Metastatic malignancies
Phase I Solid tumors
Phase I Solid tumors and lymphoma
Phase II AML and liver cancer
Phase I Lymphoid tumors
Phase I Solid tumors and lymphoma
Phase II Lung cancer
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AMSH (associated molecule with the SH3 domain of STAM)
(http://www.progenra.com/scientist.html, 2009). USP20, also
called VDU2 (von Hippel-Lindau deubiquitinating enzyme 2),
deubiquitinates and stabilizes hypoxia-inducible factor 1a (HIF-
1a) (Li et al., 2005). HIF-1a is expressed at high levels in many
human cancers because it is stabilized at the low concentration
of dissolved oxygen inside the tumor by high cytokine levels and
by specific genetic alterations. For example, in von Hippel-Lin-
dau disease, in which individuals develop a variety of tumors,
mutations in the VHL gene compromise the ubiquitination and
degradation of HIF-1a, leading to the accumulation and overex-
pression of HIF-1a and its target genes. Therefore, inhibitors of
USP20 (VDU2) and/or USP33 (VDU1) may reduce levels of HIF-
1a by enhancing its polyubiquitination.
Novartis has patented compounds that inhibit the deubiquiti-
nases USP2 and UCH-L3 (ubiquitin C-terminal hydrolase).
USP2 is another deubiquitinase reported to target MDM2, the
mouse ortholog of HDM2 (Stevenson et al., 2007), whereas
UCH-L3 probably plays a role in neurodegenerative disorders,
such as Parkinson’s disease. Recently, researchers identified
a small-molecule inhibitor of USP14, called IU1, which did not
inhibit eight other deubiquitylases tested, demonstrating the
feasibility of developing relatively specific inhibitors of these
enzymes (Lee et al., 2010). USP14 is associated with the protea-
some, and treating cells with IU1 enhanced the degradation of
several proteasomal substrates that have been implicated in
neurodegenerative diseases, such as Tau. Drugs that target
USP14 could, therefore, have a potential use in reducing or elim-
inating misfolded and aggregated proteins that accumulate in
neurodegenerative and other diseases.
Developing pharmaceutical agents that target deubiquitinases
is still in its infancy, and to our knowledge, no deubiquitinase
inhibitor has yet entered clinical trials. However, as this field
progresses, it is clearly going to be essential to assess the
specificities of these inhibitors. Therefore, assembling compre-
hensive panels of deubiquitinases for testing specificity will be
critical, similar to how large panels of protein kinases have
been of immense value in assessing the selectivity of kinase
inhibitors.
Aswith kinases, there are certainly going to be deubiquitinases
for which inhibition needs to be avoided. For example, mutating
or deleting the A20 deubiquitinase causes or predisposes indi-
viduals to inflammatory and autoimmune diseases (Musone
et al., 2008; Turer et al., 2008). Similarly, inactivating mutations
in the deubiquitinase CYLD cause cylindromatosis, a type of
skin cancer (Kovalenko et al., 2003; Trompouki et al., 2003).
Targeting E3 Ubiquitin Ligases
The human genome encodes more E3 ubiquitin ligases than
protein kinases (Table 1). Furthermore, the E3 ligase confers
specificity to ubiquitination when it transfers ubiquitin from an
E2 to a particular substrate. For these reasons, E3 ubiquitin
ligases are attractive candidates as drug targets. In some cases,
identifying compounds that disrupt the interaction of an E3 ligase
with its substrates has proven a frustrating experience for
several companies, and a number of programs have been
unsuccessful. For example, we understand that several compa-
nies have tried and failed to develop inhibitors of MuRF1, an E3
ligase involved in degrading myosin as a therapy for preventing690 Cell 143, November 24, 2010 ª2010 Elsevier Inc.muscle wasting. Nevertheless, several programs have made
good progress and a number of E3 ligase inhibitors have
advanced to clinical trials (Table 3) (reviewed in Tcherpakov,
2010). Moreover, several recent and unexpected developments
in this area are likely to enhance future pharmaceutical interest in
developing E3 ligase inhibitors.
Several companies have discovered compounds that disrupt
the interaction of the E3 ligase HDM2and its substrate, the tumor
suppressor p53, with the aim of elevating p53 expression. One
such compound, Nutlin 3/R7112, has entered clinical trials
(Table 3). A second class of E3 ligases actively targeted by
a number of companies is the Inhibitors of Apoptosis Proteins
(IAPs), and seven antagonists of IAPs have even entered clinical
trials (Table 3). These drugs are small-molecule mimetics of
Smac (also known as Diablo), a protein that antagonizes IAPs
by interacting with their BIR domains. Smac mimetics appear
to induce the autoubiquitination and degradation of the IAPs,
which then leads to the death of cancer cells by stimulating the
TNF-a pathway (Wu et al., 2007). Destruction of IAPs through
the Smacmimetics also suppresses the production of proinflam-
matory cytokines by Toll-like receptor agonists, suggesting that
these drugs may be worth exploring as possible treatments for
chronic inflammatory diseases (Tseng et al., 2010).
Recently, Ito et al. (2010) surprisingly discovered that the drug
thalidomide binds to cereblon (CRBN), a component of the Cullin
RING E3 ligase that is important for limb outgrowth and the
expression of a fibroblast growth factor (FGF8) during embryonic
development (Ito et al., 2010). This finding explained why thalid-
omide, originally prescribed as a sedative, caused multiple birth
defects in pregnant women. Thalidomide is still used for the
treatment of numerous conditions, including leprosy, skin sores,
and myelofibrosis. Therefore, pinpointing the molecular mecha-
nism of the drug’s devastating side effects may facilitate the
development of new thalidomide derivatives that are free from
this problem.
Arsenic is another drug that unexpectedly regulates an E3
ligase. Arsenic is an effective and specific treatment for acute pro-
myelocytic leukemia. In this cancer, the promyelocytic leukemia
(PML) protein becomes fused to the retinoic acid receptor (RAR).
Arsenic triggers the degradation of the PML-RAR fusion protein
by inducing the SUMOylation of PML. This modified version of
PML recruits the SUMO-binding E3 ubiquitin ligase RNF4, which
catalyzes the polyubiquitination (K48-linked) and proteasomal
degradation of the PML-RAR complex (Tatham et al., 2008).
Small-molecule inhibitors of several Cullin RING E3 ligases
have also been identified. SCFskp2 is a Cullin RING E3 ligase
that is highly expressed in some human cancers. Decreased
levels of p27kip1 are a poor prognosis factor in many malignan-
cies, and SCFskp2 ubiquitinates p27kip1, targeting it for protea-
somal destruction (Cardozo and Pagano, 2007; Merlet et al.,
2009). Researchers have identified one compound that prevents
the incorporation of Skp2 into the SCFskp2 complex, which trig-
gers cell death (i.e., autophagy) by stabilizing p27kip1 and
inducing G1/S cell-cycle arrest. This inhibitor synergizes with
Bortezomib and overcomes resistance to Bortezomib in models
of multiple myeloma. Moreover, the compound was active
against aggressive leukemia cells (i.e., leukemia blasts) and
plasma cells derived from patients (Chen et al., 2008).
SCFbTrCP1 isaCullinRINGE3 ligase that triggers thedegradation
of IkBa, the inhibitory component of the proinflammatory tran-
scription factor NF-kB. Therefore, drugs that target SCFbTrCP1
may have potential as anti-inflammatory agents, and it is of great
interest that an inhibitor of SCFbTrCP1 has been identified, which
prevents the polyubiquitination anddegradation of IkBa (Nakajima
et al., 2008).
Researchers have also identified a small-molecule inhibitor of
Cdc4, the yeast ortholog of themammalian Cullin RING E3 ligase
Fbw7 (F box and WD repeat domain-containing 7). A recent
X-ray crystal structure (Orlicky et al., 2010) revealed that the
inhibitor inserts between two of the b strands of the WD40
propeller domain of Cdc4, which are remote from the
substrate-binding site. Binding of the inhibitor induces a long-
range conformational change that distorts the substrate-binding
pocket and impedes recognition of the substrate. Thus, this
compound is one of the first allosteric inhibitors of an E3 ligase
to be identified and raises the possibility that other Cullin RING
E3 ligases with WD40 domains may possess analogous pockets
that could be targeted by inhibitors. A small-molecule inhibitor of
the SCFMet30 ligase was recently identified in a screen for small-
molecule enhancers of the drug rapamycin (Aghajan et al., 2010).
To our knowledge, none of these compounds has yet entered
clinical development, but they are proof-of-principle, demon-
strating that there is no particular fundamental barrier to identi-
fying inhibitors of the Cullin RING family of E3 ubiquitin ligases.
The Future of Ubiquitin Drug Discovery
There are striking parallels between the histories of protein phos-
phorylation and protein ubiquitination and their exploitation for
the development of drugs to treat diseases (Table 1). Both bio-
logical control mechanisms were identified many years ago,
but interest in targeting them for drug discovery only started to
take off in the 1990s. Indeed, the first compounds inhibiting
components of these systems entered clinical trials at around
the same time (Bortezomib—1997, Gleevec—1998), and these
drugs were among the fastest ever approved for clinical use
(Gleevec—2001, Bortezomib—2003). Both Gleevec and Borte-
zomib subsequently achieved ‘‘blockbuster’’ status with current
sales of about US$3 billion (Gleevec) and US$1.4 billion (Borte-
zomib) per annum.
However, that is where their similarities end. Since the devel-
opment of Gleevec, 15 other drugs targeting a specific protein
kinase have been approved for clinical use, but no other drug tar-
geting a particular component of the ubiquitin system has yet
been approved. In addition, kinase inhibitors currently under-
going clinical trials also outnumber the inhibitors of the ubiquitin
system by more than ten to one (Table 1).
Why has drug discovery in the ubiquitin system lagged so far
behind that of protein kinases, and what is needed to change
this state of affairs in the future? In retrospect, one factor driving
the kinase field forward at such a rapid pace is the ease with
which large and varied chemical libraries can be synthesized
and exploited to develop inhibitors of many protein kinases.
Further, receptor tyrosine kinases have extracellular domains
that can also be targeted with therapeutic antibodies. In
contrast, although E3 ubiquitin ligases outnumber protein
kinases, researchers still have not developed a general approachfor identifying inhibitors of many E3 ubiquitin ligases. This is
because, thus far, researchers have focused primarily on dis-
rupting the interaction between E3 ligases and their substrates,
which is specific to particular E3 ligase-substrate pairs. More-
over, finding compounds to disrupt the interface of two proteins
can be intrinsically more difficult to achieve than searching for
small molecules that block catalytic activity.
Surprisingly, little effort has been devoted to developing
compounds that disrupt the interactions between E2-conjugating
enzymes and E3 ligases. E2-E3 interactions are usually relatively
weak (Ye and Rape, 2009) and may therefore be relatively easy
to disrupt. Moreover, compounds that disturb the interaction
betweenanE2-conjugatingenzymeandanE3 ligasecould, inprin-
ciple, exert their effects by binding to the E2, the E3, or the E2-E3
interface, creating the potential to identify three types of inhibitors
from a single screen. There are 40 E2-conjugating enzymes en-
coded by the human genome; therefore, on average, each E2
must interact productively with 15 E3 ligases. Compounds that
disrupt E2-E3 interactions by binding specifically to the E3 ligase
could be identified by counterscreening with another E3 ligase
that also forms a productive interaction with the same E2. Indeed,
focusing efforts on large families of E3 ligases, such as the Cullin
RING ligases, may lead to the development of chemical libraries
with the capability of disrupting many E2-E3 interactions.
By analogy with kinases, perhaps the key to developing inhib-
itors of specific E2-E3 interactions is to find compounds that
bind to small hydrophobic pockets on E3 ligases located
proximal to the E2-E3 interface itself or to identify allosteric inhib-
itors that disrupt the E2-E3 interaction by inducing long-range
conformational changes. The three-dimensional structure of an
E2-ubiquitin thiol ester-E3 ligase complex has yet to be reported,
but such a structure might be extremely helpful in understanding
how E2-E3 interactions could be disrupted. To crystallize such
a complex, it might be necessary to stabilize the E2-ubiquitin
thiol ester-E3 interactions by including a small molecule that
inactivates E3 ligase function without affecting its ability to
bind to the E2-conjugating enzyme.
Another area where more effort will probably be fruitful is the
production of chemical libraries that target the different families
of deubiquitinases. Although inhibitors of a few deubiquitinases
are under development, such as Usp2a, Usp7, Usp20, and
Uch-L3, other deubiquitinases are also potentially rewarding
drug targets but seem to have attracted little attention so far.
For example, Usp6 is an oncogene with transforming activity; re-
arrangements and fusions of this deubiquitinase are found in
a number of cancers (Oliveira et al., 2006). Moreover, the possi-
bility of developing drugs that increase the expression and/or
activity of deubiquitinases also should not be ignored. For
example, the deubiquitinase BAP1 interacts with BRCA1, an
E3 ligase frequently mutated in breast cancer. BAP1 enhances
BRCA1-mediated inhibition of breast cancer cell growth and
may be a tumor suppressor gene that functions in the BRCA1
growth control pathway (Jensen et al., 1998). Thus, drugs that
enhance the activity or expression of BAP1 could have thera-
peutic potential for treating cancer.
Experience with protein kinases has taught us that
compounds developed as inhibitors of one protein kinase
commonly turn out to inhibit other protein kinases even moreCell 143, November 24, 2010 ª2010 Elsevier Inc. 691
potently (Bain et al., 2007) and thus can become leads in
completely different drug discovery programs. Sorafenib (also
called Nexavar), an approved drug for the treatment of renal
cell carcinoma, was originally developed as an inhibitor of
a serine/threonine kinase Raf. However, now Sorafenib is
thought to exert its therapeutic benefit by inhibiting several tyro-
sine kinases, such as the PDGF receptor (Lierman et al., 2006).
Developing chemical libraries that target deubiquitinases is likely
to yield similar surprises and likely generate drug leads for
a number of these isopeptidases.
ThesuccessofBortezomiband theadvancementof theNAE-E1
inhibitor MLN4924 into clinical trials suggest that there is vast
potential to develop more drugs targeted to general components
of the ubiquitin system. Drugs that block the same target by
distinct mechanisms can have strikingly different efficacies
because their toxicities, half-lives in vivo, and pharmaco-dynamic
properties can vary substantially. Such targetsmight include other
E1-activating enzymes (e.g., the E1s for ubiquitination and SU-
MOylation) and other components of the proteasome. For
example, Bortezomib predominantly targets the chymotrypsin-
like activity of the proteasome, and drugs that inhibit the cas-
pase-like and trypsin-like activities of the proteasome may be
more potent inhibitors or have different effects than Bortezomib.
The 19S component of the proteasome is another underex-
plored target. The 19S possesses ATPase activity, a polyubiqui-
tin-binding site, and deubiquitinase activities, all of which could
be targeted for drug development. Another possible target is
p97/VCP, a protein that plays a key role in eliminating misfolded
proteins by the endoplasmic reticulum-associated degradation
pathway (ERAD). Indeed a small-molecule inhibitor of the
ATPase activity of p97/VCP has been discovered that blocks
proliferation of cancer cell lines (T.-F. Chou et al., 2008, FASEB
J., abstract). Novel proteasome inhibitors might also be useful in
transplantation as a therapy for antibody- and cell-mediated acute
rejection (Everly et al., 2008). For example, Bortezomib has shown
promise in reducing graft-versus-host disease and in reconstitut-
ing the immune system in some stem cell transplant patients.
Inflammatory and autoimmune disorders may be treated with
selective inhibitors to a distinct class of proteasome, called the
immunoproteasome. Expressed in monocytes and lympho-
cytes, the immunoproteasome regulates many facets of the
immune response, in part by shaping the antigenic repertoire
presented on class I major histocompatibility complexes. The
immunoproteasome contains orthologs of the proteolytic activi-
ties associated with the ‘‘constitutive’’ 26S proteasome,
including a component with chymotryptic-like activity, called
LMP7. Recently, researchers developed a relatively selective
inhibitor of LMP7, which prevents the production of interleukin-
2 and interferon-g by activated T cells and interleukin-23 by acti-
vated monocytes. Furthermore, this inhibitor showed promise in
treating arthritis in mouse models (Muchamuel et al., 2009).
Finally, it is also worth noting thatMycobacterium tuberculosis
is the only bacterial pathogen known to have a proteasome.
Recently, one compound, oxathiazol-2-one, was identified with
preferential inhibition of the bacterial proteasome over the
human proteasome (Lin et al., 2009). Indeed, a selective inhibitor
of this mycobacterial proteasome might be useful for treating
tuberculosis.692 Cell 143, November 24, 2010 ª2010 Elsevier Inc.Predicting the future is notoriously difficult. However, given
the diverse approaches and avenues that remain unexplored
in developing drugs targeted at the ubiquitin system, the
authors of this article would be surprised if ubiquitin drug
discovery was not far more important in 10 years time than it
is today. Nevertheless, only time will tell if ubiquitin drug
discovery will eventually rival in its importance that of kinase
drug discovery.
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